(FAGR) Fagron - Ratings and Ratios
Pharmaceutical Compounding, Ingredients, Raw Materials
Description: FAGR Fagron
Fagron NV, a Belgian pharmaceutical company, operates in the pharmaceuticals industry, specifically within the GICS sub-industry of Pharmaceuticals. The companys stock is listed as a common stock with the ticker symbol FAGR.
To evaluate the companys financial health, we can analyze its Income Tax Expense on a yearly basis. A thorough examination of this metric can provide insights into the companys profitability and tax management strategies.
Key performance indicators (KPIs) such as Return on Equity (RoE) of 32.24% indicate that Fagron NV is generating significant returns for its shareholders, suggesting effective management and a strong business model. The companys Market Capitalization stands at 1553.24M EUR, and its Price-to-Earnings (P/E) ratio is 19.36, with a forward P/E of 16.31, indicating the markets expectations for future growth.
The pharmaceutical industry is driven by factors such as research and development (R&D) investments, regulatory environments, and demand for healthcare products. Companies like Fagron NV must navigate these drivers to maintain competitiveness. Key economic drivers for the company include the ability to innovate and bring new products to market, manage costs effectively, and adapt to changing regulatory requirements.
To further assess Fagron NVs performance, its essential to monitor its ability to maintain profitability, manage its tax obligations, and drive growth through strategic investments. Analyzing these factors can help investors make informed decisions about the companys stock.
FAGR Stock Overview
| Market Cap in USD | 1,781m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception |
FAGR Stock Ratings
| Growth Rating | 37.5% |
| Fundamental | 87.4% |
| Dividend Rating | 57.8% |
| Return 12m vs S&P 500 | -7.19% |
| Analyst Rating | - |
FAGR Dividends
| Dividend Yield 12m | 1.75% |
| Yield on Cost 5y | 1.89% |
| Annual Growth 5y | 30.26% |
| Payout Consistency | 81.6% |
| Payout Ratio | 20.2% |
FAGR Growth Ratios
| Growth Correlation 3m | -73.2% |
| Growth Correlation 12m | 78.9% |
| Growth Correlation 5y | 30% |
| CAGR 5y | 2.60% |
| CAGR/Max DD 5y | 0.05 |
| CAGR/Mean DD 5y | 0.14 |
| Sharpe Ratio 12m | -0.20 |
| Alpha | -4.20 |
| Beta | 0.802 |
| Volatility | 18.04% |
| Current Volume | 28.1k |
| Average Volume 20d | 49.3k |
| Stop Loss | 20.4 (-3.1%) |
| Signal | 0.45 |
Piotroski VR‑10 (Strict, 0-10) 8.5
| Net Income (151.1m TTM) > 0 and > 6% of Revenue (6% = 98.1m TTM) |
| FCFTA 0.14 (>2.0%) and ΔFCFTA 6.23pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 10.27% (prev 22.69%; Δ -12.43pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.20 (>3.0%) and CFO 217.3m > Net Income 151.1m (YES >=105%, WARN >=100%) |
| Net Debt (271.7m) to EBITDA (295.0m) ratio: 0.92 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.86 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (72.9m) change vs 12m ago NaN% (target <= -2.0% for YES) |
| Gross Margin 27.50% (prev 20.29%; Δ 7.21pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 156.4% (prev 67.92%; Δ 88.50pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 5.58 (EBITDA TTM 295.0m / Interest Expense TTM 43.7m) >= 6 (WARN >= 3) |
Altman Z'' 4.34
| (A) 0.15 = (Total Current Assets 362.6m - Total Current Liabilities 194.7m) / Total Assets 1.08b |
| (B) 0.24 = Retained Earnings (Balance) 264.9m / Total Assets 1.08b |
| (C) 0.23 = EBIT TTM 243.9m / Avg Total Assets 1.05b |
| (D) 0.91 = Book Value of Equity 525.3m / Total Liabilities 578.2m |
| Total Rating: 4.34 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 87.38
| 1. Piotroski 8.50pt = 3.50 |
| 2. FCF Yield 8.69% = 4.35 |
| 3. FCF Margin 9.33% = 2.33 |
| 4. Debt/Equity 0.70 = 2.26 |
| 5. Debt/Ebitda 1.19 = 1.49 |
| 6. ROIC - WACC 15.70% = 12.50 |
| 7. RoE 32.24% = 2.50 |
| 8. Rev. Trend 99.26% = 4.96 |
| 9. Rev. CAGR 18.65% = 2.33 |
| 10. EPS Trend 46.36% = 1.16 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of FAGR shares?
Over the past week, the price has changed by +1.45%, over one month by +2.18%, over three months by -3.88% and over the past year by +11.58%.
Is Fagron a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of FAGR is around 19.12 EUR . This means that FAGR is currently overvalued and has a potential downside of -9.17%.
Is FAGR a buy, sell or hold?
What are the forecasts/targets for the FAGR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 24.8 | 18% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 21.2 | 0.7% |
FAGR Fundamental Data Overview
Market Cap EUR = 1.52b (1.52b EUR * 1.0 EUR.EUR)
CCE Cash And Equivalents = 115.9m EUR (Cash And Short Term Investments, last quarter)
P/E Trailing = 17.7778
P/E Forward = 15.873
P/S = 1.6547
P/B = 3.0117
Beta = 0.252
Revenue TTM = 1.63b EUR
EBIT TTM = 243.9m EUR
EBITDA TTM = 295.0m EUR
Long Term Debt = 341.5m EUR (from longTermDebt, last quarter)
Short Term Debt = 9.50m EUR (from shortTermDebt, last quarter)
Debt = 351.0m EUR (Calculated: Short Term 9.50m + Long Term 341.5m)
Net Debt = 271.7m EUR (from netDebt column, last quarter)
Enterprise Value = 1.76b EUR (1.52b + Debt 351.0m - CCE 115.9m)
Interest Coverage Ratio = 5.58 (Ebit TTM 243.9m / Interest Expense TTM 43.7m)
FCF Yield = 8.69% (FCF TTM 152.6m / Enterprise Value 1.76b)
FCF Margin = 9.33% (FCF TTM 152.6m / Revenue TTM 1.63b)
Net Margin = 9.24% (Net Income TTM 151.1m / Revenue TTM 1.63b)
Gross Margin = 27.50% ((Revenue TTM 1.63b - Cost of Revenue TTM 1.19b) / Revenue TTM)
Tobins Q-Ratio = 3.34 (Enterprise Value 1.76b / Book Value Of Equity 525.3m)
Interest Expense / Debt = 4.05% (Interest Expense 14.2m / Debt 351.0m)
Taxrate = 22.34% (23.3m / 104.3m)
NOPAT = 189.4m (EBIT 243.9m * (1 - 22.34%))
Current Ratio = 1.86 (Total Current Assets 362.6m / Total Current Liabilities 194.7m)
Debt / Equity = 0.70 (Debt 351.0m / last Quarter total Stockholder Equity 501.4m)
Debt / EBITDA = 1.19 (Net Debt 271.7m / EBITDA 295.0m)
Debt / FCF = 2.30 (Debt 351.0m / FCF TTM 152.6m)
Total Stockholder Equity = 468.6m (last 4 quarters mean)
RoA = 13.95% (Net Income 151.1m, Total Assets 1.08b )
RoE = 32.24% (Net Income TTM 151.1m / Total Stockholder Equity 468.6m)
RoCE = 30.11% (Ebit 243.9m / (Equity 468.6m + L.T.Debt 341.5m))
RoIC = 23.58% (NOPAT 189.4m / Invested Capital 803.5m)
WACC = 7.88% (E(1.52b)/V(1.87b) * Re(8.97%)) + (D(351.0m)/V(1.87b) * Rd(4.05%) * (1-Tc(0.22)))
Shares Correlation 5-Years: 70.0 | Cagr: 0.20%
Discount Rate = 8.97% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 74.96% ; FCFE base≈123.2m ; Y1≈123.1m ; Y5≈130.4m
Fair Price DCF = 26.73 (DCF Value 1.95b / Shares Outstanding 73.1m; 5y FCF grow -0.66% → 3.0% )
Revenue Correlation: 99.26 | Revenue CAGR: 18.65%
Rev Growth-of-Growth: -0.18
EPS Correlation: 46.36 | EPS CAGR: 0.0%
EPS Growth-of-Growth: 75.59